---

$3.69

+0.0150 ( +0.41% ) 353.8K

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-04-30	Buy	21000.00	Myers Scott Dunseth
2024-06-21	Sale	-48429.00	Johnson David Michael
2024-06-21	Sale	-41581.00	Skvarka Jan
2024-06-21	Sale	-41581.00	Kariuki Enoch
2024-05-31	Sale	-9597.00	Gallagher Cam
2024-05-29	Sale	-72481.00	Walker Luke Nathaniel
2024-05-09	Sale	-3356.00	HAUSMAN DIANA
2024-02-12	Sale	-2573.00	Epperly Melissa B,
2024-02-12	Sale	-1173.00	Gallagher Cam
2024-02-05	Sale	-337500.00	HAUSMAN DIANA